Qureator is proud to announce its selection as a shortlisted finalist for the renowned Lush Prize in the Science category. This prestigious initiative awards £50,000 to projects that drive the transition toward practical, regulator-accepted non-animal testing methods.
At Qureator, our mission is to bridge the translational gap in drug discovery. Our proprietary Curiochips™ platform and “lab-in-the-loop” technology replace traditional animal models with high-fidelity, human-relevant organ-on-a-chip systems. This recognition validates our commitment to delivering better clinical predictions while reducing reliance on animal experimentation.
“Being shortlisted alongside such innovative peers underscores the industry’s shift toward human-centric biology,” said the Qureator team. We are honored to be recognized among this year’s distinguished shortlist.We extend our gratitude to the Lush Prize judges for championing the future of ethical science. Together, we are redefining the path to safer, more effective therapeutics.
View the full shortlist: https://lushprize.org/2026-prize/2026-prize-shortlist/